Arbutus Biopharma (ABUS) Downgraded by BidaskClub to “Sell”

BidaskClub lowered shares of Arbutus Biopharma (NASDAQ:ABUS) from a hold rating to a sell rating in a report released on Tuesday morning.

Several other research analysts also recently commented on the company. Zacks Investment Research downgraded Arbutus Biopharma from a hold rating to a sell rating in a research note on Wednesday, January 3rd. ValuEngine downgraded Arbutus Biopharma from a sell rating to a strong sell rating in a research note on Friday, December 15th. Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. B. Riley started coverage on Arbutus Biopharma in a research note on Friday, January 5th. They issued a buy rating and a $10.00 price objective on the stock. Finally, Wedbush downgraded Arbutus Biopharma from an outperform rating to a neutral rating and decreased their target price for the company from $9.00 to $6.00 in a research note on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $12.38.

How to Become a New Pot Stock Millionaire

Arbutus Biopharma (NASDAQ:ABUS) opened at $5.20 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 8.85 and a quick ratio of 11.03. Arbutus Biopharma has a 12 month low of $2.95 and a 12 month high of $8.25. The company has a market capitalization of $242.31, a PE ratio of -3.35 and a beta of 1.02.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $0.70 million. research analysts expect that Arbutus Biopharma will post -1.59 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP raised its stake in Arbutus Biopharma by 1.1% during the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares during the period. BlackRock Inc. raised its stake in Arbutus Biopharma by 7,615.3% during the 4th quarter. BlackRock Inc. now owns 751,314 shares of the biopharmaceutical company’s stock valued at $3,794,000 after purchasing an additional 741,576 shares during the period. Renaissance Technologies LLC raised its stake in Arbutus Biopharma by 150.7% during the 4th quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock valued at $2,033,000 after purchasing an additional 241,963 shares during the period. Hudson Bay Capital Management LP raised its stake in Arbutus Biopharma by 239.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,020,000 after purchasing an additional 282,000 shares during the period. Finally, K2 Principal Fund L.P. raised its stake in Arbutus Biopharma by 4.5% during the 4th quarter. K2 Principal Fund L.P. now owns 261,326 shares of the biopharmaceutical company’s stock valued at $1,320,000 after purchasing an additional 11,311 shares during the period. 62.14% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3294538/arbutus-biopharma-abus-downgraded-by-bidaskclub-to-sell-2.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Purple Innovation  Receiving Positive Media Coverage, Analysis Shows
Purple Innovation Receiving Positive Media Coverage, Analysis Shows
Traders Buy Shares of SPDR Gold Shares  on Weakness
Traders Buy Shares of SPDR Gold Shares on Weakness
Investors Buy Visa  on Weakness
Investors Buy Visa on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF  on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF on Weakness
CoinPoker Trading 6.1% Higher  This Week
CoinPoker Trading 6.1% Higher This Week
UNCoin 24 Hour Trading Volume Hits $0.00
UNCoin 24 Hour Trading Volume Hits $0.00


© 2006-2018 Ticker Report. Google+.